Efficacy of infliximab in psoriatic arthritis–related dactylitis and enthesopathy: Results from the IMPACT 2 trial - 21/08/11
Arthur Kavanaugh, MD, University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, La Jolla, CA, United States; Phillip Mease, MD, Seattle Rheumatology Associates, Swedish Hospital Medical Center, Seattle, WA, United States; Anna Beutler, MD, Centocor, Inc., Malvern, PA, United States; Christian Antoni, MD, Friedrich-Alexander University, Erlangen, Germany
Le texte complet de cet article est disponible en PDF. P2749 Dr. Kavanaugh has consulted and participated in clinical research sponsored by Centocor, Amgen, and Abbott Laboratories. Dr. Mease receives grant support for clinical trials and is a consultant for Centocor. Dr. Antoni is an investigator and consultant for infliximab at Centocor. Studies have been funded by research grants from Centocor (IMPACT) or have been done by Centocor (IMPACT 2). |
Vol 52 - N° 3S
P. P183 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?